MIT spin-off Gingko Bioworks was named to the CNBC Disruptor 50 List for using “genetic engineering to design and print new DNA for a variety of organisms…that can then be used for anything from killing antibiotic-resistant germs to producing artificial sweetener and cheaper perfume,” reports Tom Huddleston Jr. for CNBC.
Local biotech companies raised money to help MIT’s Bear Lab study Fragile X syndrome by competing in lawn games, writes Allison Hagan for The Boston Globe. The $30,000 raised provides “a very real chance at a success in this disease, and it’s going to have a much broader impact,” says Prof. Mark Bear.
Boston Globe reporter Jonathan Saltzman writes about how MIT alumnus Bernat Olle’s startup, Vedanta Biosciences, Inc., is looking to “collect a sample of every type of bacteria that lives in the gut.” The hope is to one day use what’s learned from this ‘library’ to help treat diseases.
Researchers from a number of universities, including MIT, have developed a new refillable, implantable device that can deliver drugs to the heart tissue to help treat a heart attack, reports Xinhua. "After a heart attack we could use this device to deliver therapy to prevent a patient from getting heart failure," explains Prof. Ellen Roche.
Prof. Andrew Lo speaks with Lisa Mullins of WBUR’s All Things Considered about investing in biotech. Lo explains that, “if we can use finance to reduce the risk, we will actually be able to bring lots more capital into the industry and be able to get therapies to patients faster.”
In this WBUR segment, Prof. Robert Langer speaks with Karen Weintraub about the challenges of bringing scientific discoveries from an academic lab to the marketplace. “The people who often do the best are the ones that are good at dealing with failure,” says Langer.
Reporting for WBUR, Karen Weintraub examines the biotech boom in Kendall Square. President Emerita Susan Hockfield notes that, “Every year there's a new wave of young people who arrive on our campuses and get inspired by what we do and then inspire us about what they'd like to do. I think that's part of the magic mix here.”
During this episode of NOVA Wonders, Professors Kristala Jones Prather and Kevin Esvelt discuss the future of genetic engineering. Speaking about the evolution of the biotech industry, Prather explains that, "the key observation that really fueled the entire biotech industry was recognizing that D.N.A. is really just a chemical, and the structure is what matters.”
MIT spinout Ginkgo Bioworks is highlighted on the 2018 CNBC Disruptor 50 list, reports CNBC’s Andrew Zaleski. Zaleski notes that Ginkgo Bioworks, “has developed an automated process for combining genetic parts that has made it the largest designer of printed DNA in the world. That breakthrough has positioned the start-up to change the face of a variety of industries.”
The Boston Globe’s Scott Kirsner discusses the impact of Cambridge biotech company Biogen, cofounded by Prof. Phil Sharp, which celebrates its 40th anniversary this year. “The company has become the biggest oak tree of the Massachusetts biotech sector,” writes Kirsner, “not only because it is still standing after four decades, but because it has dropped a lot of acorns.”
Alumni Keith Dionne and Frank Gentile, who met as graduate students in 1983, have launched a biotech company based on how cells detoxify and repair themselves, reports Jonathan Saltzman of The Boston Globe. Saltzman explains that by creating drugs to induce a process called autophagy, Dionne and Gentile hope to “help cells rid themselves of debris associated with diseases” like Alzheimer’s and Parkinson’s.
TechCrunch’s Devin Coldewey profiles ReviveMed, a biotech startup out of MIT that turns drug discovery into a big data problem. “ReviveMed’s approach is a fundamentally modern one that wouldn’t be possible just a few years ago, such is the scale of the data involved,” writes Coldeway.
Synlogic, founded by Prof. Jim Collins and Associate Prof. Tim Lu, is programming probiotic bacteria to treat certain genetic or acquired metabolic disease, reports Robin Seaton Jefferson for Forbes. One product is used for people whose bodies can’t maintain a healthy level of ammonia and “has been specifically engineered to convert the excess ammonia to a harmless metabolite,” explains Seaton Jefferson.
Co-founded by three alumni and a former professor, startup Ginkgo Bioworks uses genetic engineering to create an array of consumer and corporate products – all relying on socially conscious GMOs. The company, which is now partnering with Bayer, is “trying to reset the conversation around biotechnology: by foregrounding the benefits to consumers and advocating for transparency,” writes Sarah Zhang for The Atlantic.
MIT spinout Ginkgo Bioworks has not only maintained its founding members, but also recently raised $275 million from investors, writes Matthew Herper for Forbes. Herper predicts that excitement surrounding synthetic biology companies will continue because “private money is getting excited about the idea of designing biology.”